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OBJECTIVES: Hepatitis C virus treatment is based on the use of Pegylated or Con-
vencional Interferon combined with Ribavirin according to HCV genotype in Brazil. 
During this treatment usually it is observed adverse events that may need additional 
medications leading to increased demand on health resources. The aim of this study 
was to evaluate the impact of the costs of the additional drugs used by chronic HCV 
patients during the treatment with Pegylated or Convencional Interferons combined 
with Ribavirin. METHODS: It was used a retrospective cohort of HCV patients 
receiving medication from the Pharmacy Division and followed at the Clinical Hepa-
tology Unit from the HC-FMUSP. Using the SIGHTM (Sistema de Informação e 
Gestão Hospitalar)—PRODESP (Tecnologia da Informação), 117 patients were identi-
ﬁed as receiving treament for chronic HCV during the period of June 2005 and August 
2007. Costs were determined using the Sistema de Administração de Materiais (SAM) 
from the HC-FMUSP and were compared to Câmara de Regulação do Mercado de 
Medicamentos, ABC-Farma e DATASUS. Comercial USD  R$2.31. RESULTS: The 
total cost of convencional interferon 3 million UI was US$12,736.76, peginterferon 
2a 180 mcg US$168,739.74 and peginterferon 2b 80 mcg US$223,325.09. The con-
comitant medications were US$33,806.66 using the price from the SAM, while the 
value from the CMED would be US$557,572.16. The total cost of medications used 
by these patients was US$433,608.26, and 7.71% was due to concomitant medica-
tions. CONCLUSIONS: There is a great difference among the source of prices to 
evaluate cost of treatment and concomitant medications should be considered in 
evaluation of chronic hepatitis C patients.
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OBJECTIVES: To compare the cost-effectiveness of peginterferon alpha 2a or alpha 
2b, plus ribavirin, in the treatment of Hepatitis C virus chronic infection, from an 
institutional perspective, in the Mexican setting. METHODS: Using a decision tree, a 
Hepatitis C virus chronic infection 1-year treatment was modeled. The effectiveness of 
each treatment against genotypes 1, 2, or 3 was obtained using a previously published 
meta-analysis; the effectiveness measure was the percentage of patients who obtained 
a sustained viral response. Epidemiological data were included for genotype population 
distributions in Mexico. The utilized health care resources were derived from the 
Hepatitis C National Consensus and records from a reference hospital, whereas costs 
were obtained from purchasing records from a public institution. Costs were estimated 
using prices of 2008 and are expressed in US dollars (exchange rate of 11.14 pesos/ 1 
US$). RESULTS: The cost for drugs accounted for over 80% of total treatment cost. 
Average costs per patient treated were: $8,422.16 for peginterferon alpha 2b  ribavirin 
vs. $9452.59 for peginterferon alpha 2a  ribavirin. Effectiveness achieved in obtaining 
a case with sustained viral response for peginterferon alpha 2b  ribavirin was 12% 
higher compared to peginterferon alpha 2a  ribavirin. Average cost–effectiveness 
ratios corresponding to cost per patient with sustained viral response were $14,921.42 
for peginterferon alpha 2b  ribavirin: and $21,221.53 for peginterferon alpha 2a  
ribavirin. Incremental cost–effectiveness ratios obtained in the model show peginter-
feron alpha 2b  ribavirin treatment as the most cost–effective or dominant strategy, 
since using peginterferon alpha 2a  ribavirin has a cost of $8658.28 pesos for an 
additional patient to present sustained viral response. CONCLUSIONS: Ribavirin plus 
peginterferon alpha 2b combination was the most cost-effective treatment, in the 
Mexican context, according to the proposed decision tree model.
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OBJETIVOS: Efetuar estudo farmacoeconômico da racionalização da prescrição do 
omeprazol na Unidade de Terapia Intensiva (UTI) da Neurologia de um Hospital geral, 
com especialidades terciárias, publicas e de grande porte pela intervenção farmacêu-
tica, diminuindo o gasto e sistematizando o uso do omeprazol em todas as vias de 
administração. MÉTODOS: Estudo transversal, prospectivo das prescrições e pron-
tuários médicos de pacientes internados na UTI da Clínica de Neurologia, no período 
de 15 de julho de 2008 a 31 de outubro de 2008. Os instrumentos utilizados foram 
planilhas do Excel®2003 e ﬁcha de interconsulta, preenchida pelo farmacêutico, onde 
eram anotadas as intervenções efetuadas junto ao médico, para alteração da forma 
farmacêutica IV para oral (VO) ou por sonda nasoenteral (SNE) se o paciente apre-
sentasse condições de deglutição ou se estivesse utilizando SNE. Para a avaliação 
farmacoeconômica efetuou-se a diferença entre os valores dos tratamentos intraveno-
sos, por sonda SNE e VO. RESULTADOS: A média de idade e de internação foi 48.8 
anos e 15.2 dias respectivamente. Dos 92 pacientes internados no período de estudo, 
2 não utilizavam omeprazol (critério de exclusão) e 90 utilizavam omeprazol IV como 
proﬁlaxia de úlcera de estresse. Foram efetuadas 58 intervenções farmacêuticas, das 
quais 25 (43%) não foram aceitas, pois 18 não possuíam acesso por via oral ou por 
SNE e 7 tiveram alta hospitalar. Foram aceitas 33 intervenções, sendo 16 (48.5%), 
mudaram de IV para via oral e 17 (51.5%) mudaram de IV para SNE. O valor total 
do tratamento sem a intervenção farmacêutica seria R$ 10,928.34, com a intervenção 
o valor gasto foi de R$ 2,738.03. CONCLUSÕES: A intervenção farmacêutica na 
Unidade de Terapia Intensiva diminuiu a utilização do omeprazol IV, e o estudo 
farmacoeconômico demonstrou que a economia no período analisado, quanto ao uso 
de omeprazol na UTI foi R$ 8,190.31 (74.9%).
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OBJECTIVES: This analysis evaluates impact on costs for treatment of patients with 
Chronic Hepatitis C (CHC), in case that valid guidelines are not followed. METHODS: 
A retrospective analysis of patients data, year 2004, from 15 Slovak hepatology centers 
was used. Data for respective costs were collected from published sources. Decision 
tree model was developed to evaluate overall costs when quantitative HCV RNA test 
is used for treatment termination. Costs in Euro were calculated with ofﬁcial exchange 
rate a30,126 Sk. RESULTS: Published national guidelines for CHC required examina-
tion of quantitative HCV RNA after 12 weeks of treatment in patients with genotype 
1 to detect early virological response (EVR) and treatment termination in case of 
negative results of EVR. Quantitative HCV RNA test was not performed, because it 
was not reimbursed by insurance companies at that time. Omission of EVR examina-
tion led to ungrounded prolongation of treatment in patients without EVR response. 
From the group of 140 patients with chronic hepatitis there were 94 patients with 
CHC (average age 41 years, weight 73 kg). Genotype 1 was conﬁrmed in 57 patients, 
genotype 2 and 3 in 33 patients and unknown genotype in 4 patients. Patients were 
treated with combination of pegylated interferon alpha and ribavirin. Total treatment 
costs for 57 patients with HCV genotype 1 were a1,672,393. Decision tree model 
taking into account EVR results (followed by appropriate treatment termination) cal-
culated that treatment cost in this group of 57 patients would be a1,378 273. CON-
CLUSIONS: Signiﬁcant saving of costs could be achieved when valid treatment 
guidelines for CHC are followed in everyday practice. In analyzed group of 57 patients 
with HCV genotype 1, this savings would be a294,120. This study underline impor-
tance of preparation and implementation of clinical practice guidelines in national 
health and drug policy.
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OBJECTIVES: The objective of this study was to compare the cost-effectiveness of 
open mesh versus open non mesh inguinal hernia repair in Brazil from private hospital 
and private payer perspectives. METHODS: Cost-effectiveness of open mesh vs open 
non mesh repair was modeled using a Markov model. Model was evaluated as a cohort 
simulation for a time horizon up to 15 years. Transition probabilities were derived 
from systematic review and other published sources. Resource utilization data were 
collected from two private hospitals and a private payer in Brazil. Utility values 
were extracted from published sources. Both costs and outcomes were discounted 
annually at 5%. RESULTS: Over both a ﬁve and ﬁfteen year period, open mesh repair 
provides greater beneﬁts in terms QALYs and fewer recurrences at a cumulatively 
higher cost than open non mesh repair procedures. Over a 5 and 15-year time frame, 
cost per one additional QALY is R$17,843 and R$2,991 respectively from a payer 
perspective and R$12,825 and R$957 respectively from a hospital perspective. Simi-
larly, the cost per one recurrence avoided is 1162 R$ and R$245 in a ﬁve and ﬁfteen 
years time horizon from payer perspective (R$836 and R$79 respectively from a hos-
pital perspective). Results in the probabilistic sensitivity analysis were similar to deter-
ministic analysis. In the ﬁve year perspective open mesh repair is more cost effective in 
comparison to open non mesh repair when the value for society’s willingness to pay 
threshold for a QALY exceeds R$8000 for a life year (Zero R$ in the 15 years in both 
perspectives). CONCLUSIONS: Findings suggest that in Brazil, open mesh inguinal 
hernia repair is cost effective from both private hospitals and private payer perspectives 
and should be considered standard of care based on superior outcomes and costs.
